TCON - TRACON Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.60
-0.05 (-1.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.65
Open2.60
Bid2.45 x 4000
Ask4.50 x 1000
Day's Range2.55 - 2.65
52 Week Range2.00 - 3.95
Volume68,484
Avg. Volume130,912
Market Cap77.301M
Beta1.70
PE Ratio (TTM)N/A
EPS (TTM)-1.17
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.38
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    TRACON Announces Presentation of Preclinical Data from Studies of TRC105 in Combination with a PD-1 Antibody in Murine Models of Colorectal Cancer

    SAN DIEGO, June 13, 2018-- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of TCON earnings conference call or presentation 9-May-18 8:30pm GMT

    Q1 2018 TRACON Pharmaceuticals Inc Earnings Call

  • GlobeNewswire2 months ago

    TRACON Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

    SAN DIEGO, May 31, 2018-- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related ...

  • GlobeNewswire2 months ago

    TRACON Pharmaceuticals Reports Granting of Inducement Award

    TRACON Pharmaceuticals (TCON), a biopharmaceutical company that develops targeted therapies for cancer and wet age-related macular degeneration, announced today that it has issued an inducement award to a new executive employee. In connection with the appointment of Mark Wiggins as Chief Business Officer, Mr. Wiggins was issued an inducement award consisting of an option to purchase an aggregate of 280,000 shares of the Company's common stock.  The option was granted in accordance with NASDAQ Listing Rule 5635(c)(4) under the Tracon Pharmaceuticals, Inc. 2015 Equity Incentive Plan (the "2015 Plan”) and was approved by TRACON’s compensation committee.  The option has an exercise price per share equal to $2.75, which was the closing price of TRACON’s common stock on the Nasdaq Global Market on the date of grant.

  • GlobeNewswire2 months ago

    TRACON Pharmaceuticals Appoints Biotech Industry Veteran Mark Wiggins as Chief Business Officer

    TRACON Pharmaceuticals (TCON), a biopharmaceutical company that develops targeted therapies for cancer and wet age-related macular degeneration, announced today that it has appointed Mark Wiggins as Chief Business Officer, effective immediately.  Mr. Wiggins has over 30 years of business development and commercial experience in senior roles in the biotech industry.  He will be responsible for corporate and business development and report directly to Charles Theuer, M.D., Ph.D., President and CEO of TRACON. “Mark’s business development and commercialization experience, as well as his strategic vision, will be invaluable as we continue to advance our clinical programs and leverage our product development platform. Previously, Mr. Wiggins served as Senior Vice President of Corporate and Business Development at Elcelyx Therapeutics, and Chief Business Officer at Mpex Pharmaceuticals.

  • Associated Press2 months ago

    Tracon: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 46 cents. The antibody drug developer posted revenue of $3 million in the period. In the final minutes of trading on Wednesday, the ...

  • GlobeNewswire2 months ago

    TRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

    SAN DIEGO, May 09, 2018-- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age‐ related ...

  • GlobeNewswire2 months ago

    TRACON to Report First Quarter 2018 Company Highlights and Financial Results on May 9, 2018

    SAN DIEGO, May 02, 2018-- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of TCON earnings conference call or presentation 28-Feb-18 9:30pm GMT

    Q4 2017 TRACON Pharmaceuticals Inc Earnings Call

  • Associated Press5 months ago

    Tracon reports 4Q loss

    The San Diego-based company said it had a loss of 37 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...

  • ACCESSWIRE5 months ago

    TRACON Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 28, 2018 / TRACON Pharmaceuticals, Inc. (NASDAQ: TCON ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018 at 4:30 ...

  • Benzinga5 months ago

    TRACON Pharmaceuticals Q4 Earnings Preview

    On Wednesday, TRACON Pharmaceuticals (NASDAQ: TCON ) will report its last quarter's earnings. Here is Benzinga's take on the company's release. Earnings and Revenue Sell-side analysts are expecting TRACON ...

  • Analysts Expect Breakeven On The Horizon For TRACON Pharmaceuticals Inc (NASDAQ:TCON)
    Simply Wall St.5 months ago

    Analysts Expect Breakeven On The Horizon For TRACON Pharmaceuticals Inc (NASDAQ:TCON)

    TRACON Pharmaceuticals Inc’s (NASDAQ:TCON): TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases.Read More...

  • Did TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) Recent Earnings Growth Beat The Trend?
    Simply Wall St.5 months ago

    Did TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) Recent Earnings Growth Beat The Trend?

    Today I will examine TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) latest earnings update (30 September 2017) and compare these figures against its performance over the past couple of years, in addition toRead More...

  • TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
    Capital Cube7 months ago

    TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017

    Categories: Yahoo FinanceGet free summary analysis TRACON Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of TRACON Pharmaceuticals, Inc. – Atara Biotherapeutics Inc, BioCryst Pharmaceuticals, Inc. and AVEO Pharmaceuticals, Inc. (ATRA-US, BCRX-US and AVEO-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)